Vanda Pharmaceuticals (VNDA) Tops Q3 EPS by 5c ; Offers Guidance
Tweet
Share
E-mail
Get Alerts VNDA Hot Sheet
Price: $5.95 -0.83%
EPS Growth %: -30.4%
Financial Fact:
Net income (loss): -430K
Today's EPS Names:
CBRS, MAYS, CRMT, More
EPS Growth %: -30.4%
Financial Fact:
Net income (loss): -430K
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q3 EPS of ($0.38), $0.05 better than the analyst estimate of ($0.43). Revenue for the quarter came in at $56.26 million versus the consensus estimate of $58.83 million.
GUIDANCE:
Vanda Pharmaceuticals sees FY2025 revenue of $210-230 million, versus the consensus of $224.8 million.
For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- KeyBanc Upgrades Nucor (NUE) to Overweight
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
